Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-26

Study Completion Date

2024-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of Early Memantine Administration on Outcome of Participents with Moderate to Severe Traumatic Brain Injury

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury

NCT06337994

Treatment of Cognitive Deficits After Traumatic Brain Injury

COMPLETED PHASE3

Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

NCT04417543

Epilepsy

COMPLETED PHASE1

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

NCT01261741

Memory Disorder Retention Disorder, Cognitive Subjective Cognitive Impairment +1 more

COMPLETED PHASE2

The Use of Memantine for Prevention of Alzheimer's Disease

NCT05063851

Alzheimer Disease

ACTIVE_NOT_RECRUITING PHASE2

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

NCT00322153

Dementia of the Alzheimer's Type

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studying the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in participents with moderate to severe TBI as well as outcome.

Investigators evaluate prognostic effect of memantine on participents with moderate to severe TBI. also to estimate which of platelet, platelet/lymphocyte ratio (PLR), C reactive protein (CRP) or serum NSE levels will be affected by administration of memantine in participents with moderate to severe TBI as a predictor of outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group (group 1)

Patients in the control group (group 1) No memantine administration

Group Type NO_INTERVENTION

No interventions assigned to this group

Treatment group (group 2)

in addition to the standard treatment, they will receive memantine (30 mg) twice daily, either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital. The memantine dose administered in our study was based on the maximum dose of 60 mg/day reported in prior human studies

Group Type ACTIVE_COMPARATOR

Memantine Hydrochloride

Intervention Type DRUG

study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Memantine Hydrochloride

study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Namenda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe closed TBI with initial GCS of 4-12
* Age from 18 to 65 years of both sexes
* Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI.

Exclusion Criteria

* Open TBI or patients who would need open craniotomy later on.
* Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours, acute or chronic renal insufficiency, hepatic diseases, autoimmune abnormalities, history of epileptic fits and known malignancies.

Patients with chest, cardiac, abdominal trauma or any other trauma requiring mechanical ventilation.

Patients with body mass index (BMI) \<18.5 or \> 34.9 kg/m2.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No